On the other hand, the contribution of GLP-1R to BAT activation is likely secondary to G49 actions in the central nervous system (CNS) (i.e., Th mRNA) where GLP-1Rs are highly expressed in the hypothalamus 54 and to the activation of GLP-1R-mediated pancreatic insulin secretion-driven de novo lipogenesis and the subsequent series of metabolic events discussed above
In 4-5 months, with breaks in between, I lost about 10 kg
Many women describe finally feeling in control of their eating rather than controlled by cravings and hunger
17,22, This provides a rationale for using GLP-1 together with GIP agonism, as GLP-1 may lower glucose sufficiently to unmask the incretin effect of GIP, while GLP-1 action may overcome the potentiating effect of GIP on GCG secretion
As T2D is often associated with having a high body mass index, one would be forgiven for assuming that the needs of people who use GLP-1s for weight loss and those using it to treat diabetes would be very similar, but recent market research suggests a number of significant differences:5 The majority of people using GLP-1s for weight loss are in their 30s to 50s (often as part of a wider strategy to be proactive about their health), whereas those using GLP-1s for diabetes control are more likely to be over 60
However, this effect might be independent of changes in visceral fat accumulation since previous studies have demonstrated that the hepatic glucose production is decreased in healthy individuals following acute administration of both native GLP-1 (44)
